Real‐world glycaemic outcomes observed with the use of Medtronic 780G , Tandem Control‐ IQ and Omnipod 5 automated insulin delivery systems
Authors' conclusion
All three hybrid AID systems were associated with improvements in glycaemic outcomes in real-world use, supporting the role of AID systems in the management of T1D. Medtronic 780G use was associated with higher TIR increase compared with the other systems; however, these findings are based on measurements from different continuous glucose monitors between AID groups and cannot be used to infer superiority in glycaemic attainment.
Study context
- Population
- Adults with T1D transitioning from multiple daily injections (MDI) or non-automated insulin pump therapy to hybrid automated insulin delivery (AID)
- Participants
- 213 adults
- Exposure
- Medtronic 780G vs Tandem Control-IQ vs Omnipod 5 hybrid AID systems
- 780Gn = 38
- Control-IQn = 81
- Omnipod 5n = 94
- Outcome
- Time in range (TIR) increase (3.9-10.0 mmol/L), adjusted for baseline TIR, diabetes duration, insulin modality and AID use duration
Methodological detailsobservational, single-centre, Data from clinical data-sharing platforms and electronic health records
- Observational
- Single-centre
- Data from clinical data-sharing platforms and electronic health records
Main finding
As reported in the abstract
780G vs Control-IQ: P = 0.010 · 780G vs Omnipod 5: P = 0.002
Observational data: associations, not effects.
Original publication
Real‐world glycaemic outcomes observed with the use of Medtronic 780G , Tandem Control‐ IQ and Omnipod 5 automated insulin delivery systems. Diabet Med. Published 12 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →